Impact of Calcineurin Inhibitors on Hepatitis C Recurrence After Liver Transplantation
Impact of Calcineurin Inhibitors on Hepatitis C Recurrence After Liver Transplantation
复制标题
DOI：
10.1007/s10620-011-1871-z
复制
发表时间：
2012-02-01
影响因子：
3.1
通讯作者：
Fujita, Shiro
中科院分区：
文献类型：
--
作者：
Kim, Robin D.;Mizuno, Shugo;Fujita, Shiro
本回顾性研究的目的是评估钙调磷酸酶抑制剂对肝移植后丙型肝炎病毒复发的影响。我们检查了接受环孢素（n = 126）或他克莫司（n = 270）作为维持免疫抑制的患者的术前和术后特征。此外，我们还比较了两组的术后病程，包括患者、移植物和丙型肝炎病毒无复发生存率，两组的术后丙型肝炎病毒核糖核酸或组织学纤维化评分（根据方案在移植后6个月内进行）均无显著差异。两组之间的移植物和患者生存率没有差异（logrank p分别= 0.34和0.15）。然而，环孢素组的组织学丙型肝炎病毒无复发生存率显著高于他克莫司组（1年时55.4 vs. 30.8%，3年时18.6 vs. 10.3%，5年时16.7 vs. 8.1%，丙型肝炎病毒移植患者接受环孢素治疗比接受他克莫司治疗可能有更高的无复发生存率。
The aim of this retrospective study is to assess the impact of calcineurin inhibitors on hepatitis C virus recurrence following liver transplantation.A total of 396 patients underwent liver transplantation for hepatitis C virus-induced liver disease between 1991 and 2005 at a single center. We examined the pre- and post-operative characteristics of patients who received either cyclosporine (n = 126) or tacrolimus (n = 270) as maintenance immunosuppression. In addition, we compared the postoperative course, including patient, graft and hepatitis C virus recurrence-free survival between the two groups.There were no significant differences between the two groups in either post-operative hepatitis C virus-ribonucleic acid or histological fibrosis score (performed within 6 months after transplant per protocol). The graft and patient survivals did not differ between the two groups (logrank p = 0.34 and 0.15, respectively). Histologic hepatitis C virus recurrence-free survival, however, was significantly higher in the cyclosporine group than in the tacrolimus group (55.4 vs. 30.8% at 1 year, 18.6 vs. 10.3% at 3 years, 16.7 vs. 8.1% at 5 years, p < 0.001).Patients transplanted for hepatitis C virus and treated with cyclosporine versus tacrolimus may have a higher recurrence-free survival.